{"protocolSection": {"identificationModule": {"nctId": "NCT00944125", "orgStudyIdInfo": {"id": "L-08-166"}, "organization": {"fullName": "Aurora Health Care", "class": "OTHER"}, "briefTitle": "Dual Site Left Ventricular (LV) Pacing", "officialTitle": "Dual Site LV Pacing Study: Prospective Randomized Blinded Crossover Study of Patients Meeting Current CRT-D Indication to be Implanted With Dual LV Pacing Leads and Paced Chronically for at Least 6 Months Post-implant.", "acronym": "DIVA"}, "statusModule": {"statusVerifiedDate": "2016-03", "overallStatus": "TERMINATED", "whyStopped": "for administrative reasons (no safety concerns), no analysis completed", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-06"}, "primaryCompletionDateStruct": {"date": "2013-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-07-17", "studyFirstSubmitQcDate": "2009-07-22", "studyFirstPostDateStruct": {"date": "2009-07-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-02-25", "resultsFirstSubmitQcDate": "2016-03-02", "resultsFirstPostDateStruct": {"date": "2016-03-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-03-02", "lastUpdatePostDateStruct": {"date": "2016-03-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Imran Niazi", "investigatorTitle": "Physician of Aurora Health Care", "investigatorAffiliation": "Aurora Health Care"}, "leadSponsor": {"name": "Imran Niazi", "class": "OTHER"}, "collaborators": [{"name": "Medtronic", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare Dual LV (left ventricular) pacing to standard single LV pacing (BiV pacing) to see if Dual LV pacing:\n\n1. Improves the way the heart's left ventricle functions\n2. Decreases the number of hospital and clinic visits for heart failure related symptoms\n3. Slows the rate patients experience certain heart failure symptoms\n4. Reduces uncoordinated heart contractions"}, "conditionsModule": {"conditions": ["Congestive Heart Failure", "LV Dysfunction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 50, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dual Site LV Pacing", "type": "ACTIVE_COMPARATOR", "description": "Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.", "interventionNames": ["Device: Dual Site LV Pacing", "Device: BiV Pacing"]}, {"label": "BiV Pacing", "type": "ACTIVE_COMPARATOR", "description": "Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.", "interventionNames": ["Device: Dual Site LV Pacing", "Device: BiV Pacing"]}], "interventions": [{"type": "DEVICE", "name": "Dual Site LV Pacing", "description": "Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.", "armGroupLabels": ["BiV Pacing", "Dual Site LV Pacing"]}, {"type": "DEVICE", "name": "BiV Pacing", "description": "Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.", "armGroupLabels": ["BiV Pacing", "Dual Site LV Pacing"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Left Ventricular End Systolic Volume (LVESV)", "description": "The change in LVESV during the single and dual site LV pacing phases from baseline will be compared. The baseline for the second phase of the cross-over will be the end of phase one rather than the baseline done at time of randomization. Thus, the study will compare the incremental (or decremental) benefit of the alternate LV pacing configuration in each patient.", "timeFrame": "At 6 months to one year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Moderate or severe heart failure, defined as NYHA Class III-IV despite optimal pharmacological heart failure therapy\n* On heart failure medical regimen (beta blockers and ACE-I or ARB's) for at least one month before randomization\n* A 12-lead electrocardiogram (ECG) obtained no more than 90 days prior to enrollment documenting a QRS duration \\> 120 ms\n* Left ventricular ejection fraction (LVEF) \\< 35% or equal\n* Willing and capable of undergoing the device implant procedure and participating in all testing associated with this clinical study\n* Have a life expectancy of more than 180 days, per physician discretion\n* Age 40 or above, ensuring of legal age to give informed consent specific to state and national law\n\nExclusion Criteria:\n\n* Have had previous cardiac resynchronization therapy or a previous coronary venous lead\n* Unable to perform a Six-Minute Hall Walk (6MHW) Test\n* Have an atrial tachyarrhythmia that is permanent (i.e., does not terminate spontaneously and cannot be terminated with medical intervention)without CHB or planned AVJ ablation prior to randomization\n* Have an atrial tachyarrhythmia that is persistent (i.e. can be terminated with medical intervention, but does not terminate spontaneously) without planned and successful cardioversion prior to randomization (patients with unsuccessful cardioversions and no AVJ Ablation will be exited.)\n* Have hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g., amyloidosis, sarcoidosis)\n* Have a mechanical tricuspid prosthesis\n* Has severe aortic or mitral stenosis\n* Enrolled in any concurrent study that may confound the results of this study\n* Patients who are or suspect they may be pregnant or plan to become pregnant", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "40 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Imran K Niazi, MD", "affiliation": "Aurora Health Care", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Aurora Cardiovascular Services", "city": "Lake Geneva", "state": "Wisconsin", "zip": "53147", "country": "United States", "geoPoint": {"lat": 42.59168, "lon": -88.43343}}, {"facility": "Aurora Cardiovascular Services", "city": "Milwaukee", "state": "Wisconsin", "zip": "53215", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects are consented and randomized before the pacing prodecure. They may have been excluded (considered screen fails) if they end up not having the procedure or being identified as inappropriate once the procedure began. 50 Consented and 41 Randomized.", "groups": [{"id": "FG000", "title": "Dual Site LV Pacing First, Then BiV Pacing, Then Physician Dis", "description": "Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.\n\nRandomized to Dual Site LV Pacing for three months then crossed over to standard BIV pacing for three months then programmed per physician discretion for the remainder three months."}, {"id": "FG001", "title": "BiV Pacing First, Then Dual Site LV Pacing, Then Physician Dis", "description": "Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.\n\nRandomized to standard BiV pacing for three months then crossed over to Dual LV pacing for three months, then programmed per physician discretion for the remainder of the study."}], "periods": [{"title": "Baseline to 3 Months", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "3 to 6 Months", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}, {"title": "6 Months to Study Completion", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Includes both randomized groups, Group A: Randomized to Dual LV pacing for three months then crossed over to Standard BiV pacing for three months, then programmed at the physician discretion. Group B: Randomized to Standard BiV pacing for three months then crossed over to Dual LV pacing for three months, then programmed to physician discretion.", "groups": [{"id": "BG000", "title": "All Study Participants", "description": "Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.\n\nRandomized to Arm A: Dual Site LV Pacing for three months then crossed over to standard BIV pacing for three months then programmed per physician discretion for the remainder three months. Randomized to Arm B: Randomized to standard BiV pacing for three months then crossed over to Dual LV pacing for three months, then programmed per physician discretion for the remainder of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "50"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "69.5", "spread": "10.98"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "20"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "30"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "50"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Left Ventricular End Systolic Volume (LVESV)", "description": "The change in LVESV during the single and dual site LV pacing phases from baseline will be compared. The baseline for the second phase of the cross-over will be the end of phase one rather than the baseline done at time of randomization. Thus, the study will compare the incremental (or decremental) benefit of the alternate LV pacing configuration in each patient.", "populationDescription": "Analysis population was based on the two randomized groups per the protocol.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ml", "timeFrame": "At 6 months to one year", "groups": [{"id": "OG000", "title": "Dual Site LV Pacing"}, {"id": "OG001", "title": "BiV Pacing"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-28.16", "spread": "14.62"}, {"groupId": "OG001", "value": "-25.91", "spread": "27.84"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "1 year", "description": "Adverse Events were collected per intervention.", "eventGroups": [{"id": "EG000", "title": "Dual Site LV Pacing", "description": "Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.\n\nRandomized to Dual Site LV Pacing for three months then crossed over to standard BIV pacing for three months then programmed per physician discretion for the remainder three months.", "seriousNumAffected": 3, "seriousNumAtRisk": 41, "otherNumAffected": 10, "otherNumAtRisk": 41}, {"id": "EG001", "title": "BiV Pacing", "description": "Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.\n\nRandomized to standard BiV pacing for three months then crossed over to Dual LV pacing for three months, then programmed per physician discretion for the remainder of the study.", "seriousNumAffected": 3, "seriousNumAtRisk": 41, "otherNumAffected": 3, "otherNumAtRisk": 41}], "seriousEvents": [{"term": "Syncope", "organSystem": "Vascular disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "A disorder characterized by spontaneous loss of consciousness caused by insufficient blood supply to the brain.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}]}, {"term": "Dyspnea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "disorder characterized by an uncomfortable sensation of difficulty breathing.", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}]}, {"term": "Heart failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "(exacerbation of existing condition) A disorder characterized by the inability of the heart to pump blood at an adequate volume to meet tissue metabolic requirements, or, the ability to do so only at an elevation in the filling pressure.", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "(not related to investigation)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}]}, {"term": "Multi-organ failure", "organSystem": "General disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "(not related to investigation) A disorder characterized by progressive deterioration of the lungs, liver, kidney and clotting mechanisms.", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}]}, {"term": "Sepsis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "A disorder characterized by the presence of pathogenic microorganisms in the blood stream that cause a rapidly progressing systemic reaction that may lead to shock.", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}]}, {"term": "Fall", "organSystem": "General disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "A finding of sudden movement downward, usually resulting in injury.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}]}, {"term": "Chest pain - cardiac", "organSystem": "Cardiac disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "A disorder characterized by pathological irregularities in the cardiac conduction system.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}]}, {"term": "Hyperkalemia", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "A disorder characterized by laboratory test results that indicate an elevation in the concentration of potassium in the blood; associated with kidney failure or sometimes with the use of diuretic drugs.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}]}, {"term": "Gastrointestinal disorders - Other, specify", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "GI bleed, non specific", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}]}, {"term": "Stomach pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "A disorder characterized by a sensation of marked discomfort in the stomach.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}]}, {"term": "Rectal fistula", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "A disorder characterized by an abnormal communication between the rectum and another organ or anatomic site.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}]}, {"term": "ICD shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}]}, {"term": "Lead dislodgement", "organSystem": "Cardiac disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}]}, {"term": "Anemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "A disorder characterized by an reduction in the amount of hemoglobin in 100 ml of blood.", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}]}], "otherEvents": [{"term": "Diaphragmatic Stimulation", "organSystem": "General disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Simulation of the phrenic nerve or diaphragm by a pacing output pulse, causing a hiccough-like reaction.", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 41}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "CTCAE v4.0.3", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Study terminated early form administrative reasons (no safety concerns), no analysis was completed."}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Imran K. Niazi, MD", "organization": "Aurora Health Care", "email": "imran.niazi@aurora.org", "phone": "414-645-6070"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Congestive Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}